1. Home
  2. EXFY vs ELTX Comparison

EXFY vs ELTX Comparison

Compare EXFY & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expensify Inc.

EXFY

Expensify Inc.

HOLD

Current Price

$1.41

Market Cap

132.1M

Sector

Technology

ML Signal

HOLD

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$8.04

Market Cap

141.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXFY
ELTX
Founded
2008
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
132.1M
141.3M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
EXFY
ELTX
Price
$1.41
$8.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$4.50
$13.00
AVG Volume (30 Days)
614.9K
89.8K
Earning Date
02-26-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$143,907,000.00
N/A
Revenue This Year
$4.42
N/A
Revenue Next Year
$0.58
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.71
N/A
52 Week Low
$1.33
$4.60
52 Week High
$4.00
$12.62

Technical Indicators

Market Signals
Indicator
EXFY
ELTX
Relative Strength Index (RSI) 40.75 49.61
Support Level $1.42 $7.77
Resistance Level $1.57 $8.64
Average True Range (ATR) 0.06 0.34
MACD -0.01 0.06
Stochastic Oscillator 8.50 51.66

Price Performance

Historical Comparison
EXFY
ELTX

About EXFY Expensify Inc.

Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.

Share on Social Networks: